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Abstract 
This study was designed to evaluate the mydriatic effects of patients being dilated under differing 
illumination conditions. Twenty subjects, ten females and ten males had their pupils dilated under 
darkened conditions and under normal illumination to determine if there would be a difference in the rate 
of mydriasis, or overall pupil size at the point of maximum dilation. Iris color and gender were separately 
evaluated factors in dilation results. Subjects were dilated using one drop each of tetracaine 1%, 
phenylephrine HCI 2.5%, and tropicamide 1%. Pupil diameter was periodically measured using a Cogan's 
pupilometer starting 6 minutes after drop instillation. Measurements with the pupilometer were taken at 
two minute intervals throughout the 30 minute test period. The final measurement 33 minutes after 
instillation of the dilating drops was taken with a biomicroscope reticule, both horizontal and vertical 
diameters were measured. No significant differences were seen between gender, iris color, or illumination 
type on the rate of maximum mydriasis. However, the relative pupil area was significantly greater 
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ABSTRACT 
The effect of illumination on the time to, 
and pupil area of, maximum mydriasis 
This study was designed to evaluate the mydriatic effects of patients being 
dilated under differing illumination conditions. Twenty subjects, ten females and 
ten males had their pupils dilated under darkened conditions and under normal 
illumination to determine if there would be a difference in the rate of mydriasis, or 
overall pupil size at the point of maximum dilation. Iris color and gender were 
separately evaluated factors in dilation results. Subjects were dilated using one 
drop each of tetracaine 1%, phenylephrine HCI 2.5%, and tropicamide 1%. Pupil 
diameter was periodically measured using a Cogan's pupilometer starting 6 
minutes after drop instillation. Measurements with the pupilometer were taken at 
two minute intervals throughout the 30 minute test period. The final measurement 
33 minutes after instillation of the dilating drops was taken with a biomicroscope 
reticule, both horizontal and vertical diameters were measured. No significant 
differences were seen between gender, iris color, or illumination type on the rate of 
maximum mydriasis. However, the relative pupil area was significantly greater 
following dilation under normal illumination conditions. 
Keywords: mydriasis, illumination, phenylephrine, tropicamide, rate 
time, light, dark, pupil, dilation, dilation rate. 
You have just finished placing the mydriatic agents into the eyes of your 
patient; do you now seat them in a dark or well lit room? Several studies have 
explored how drop size, patient age or iris color effects dilation rates and final pupil 
size; however, few studies have considered the effect of room illumination upon 
pharmaceutical induced mydriasis. 
· Despite patient inconvenience and increased examination time, dilated 
fundus exams are becoming more routine in today's optometric practice. To reach 
an acceptable mydriatic state for optimal retinal viewing requires 20-30 minutes 
after the instillation of the mydriatic drops; yet, the procedure for a thorough 
evaluation of the retina may only require a few minutes. In today's fast paced 
world, time spent waiting for the patient to dilate is a valuable commodity to both 
the patient and the optometrist. Therefore, any factor which could provide a faster 
or more complete mydriasis should be investigated; especially, an option as simple 
as placing the patient in either a light or dark environment while the drug takes 
effect. 
Several pharmaceuticals, in varying concentrations, are available for the 
use of dilating patients. However, the clinical drug of choice continues to be 
phenylephrine HCL 2.5% and tropicamide 1% (Alldredge, 1996). For this reason, 
we chose to use this drug combination to evaluate the effect of illumination on the 
dilation process. 
Drug characteristics of Phenylephrine HCL · 
Phenylephrine is a direct-acting alpha adrenergic agent which provides 
mydriasis without cycloplegic effects. It may also be used as an ocular 
decongestant or to break or prevent posterior synechia in uveitis (Rengstorff and 
Doughty, 1982). Phenylephrine 2.5% is the recommended concentration for 
routine fundus examinations. At this concentration, maximum mydriasis should 
occur within 15-60 minutes post-drop. Recovery to pre-drop pupil size will most 
likely occur in 3 hours (Bartlett et at, 1994). 
Clinically, topical use of 2.5% phenylephrine in conjunction with puncta! 
occlusion induces few serious side effects, but there may be mild ocular reactions. 
These mild ocular reactions include transient stinging upon instillation, irritation, 
headache, brow ache, blurred vision, transient epithelial kerititis, allergic reactions, 
and reactive hyperemia (Bartlett eta!, 1994). Repeated doses of phenylephrine 
may cause rebound miosis or reduce the mydriatic affect needed for ophthalmic 
surgery. Therefore, excessive or repeated use with elderly patients should be 
avoided (Bartlett et at, 1994). 
Systemic complications are primarily cardiovascular in nature and include: 
palpitations, tachycardia, arrhythmia's, hypertension, reflex bradycardia, coronary 
occlusion, pulmonary embolism, subarachnoid hemorrhage, myocardial infarction, 
stroke, and even death (Bartlett et at, 1994). 
Caution is recommended when using phenylephrine with patients who have 
cardiac disease, hypertension, atherosclerosis, diabetes or who are pregnant. It 
should not be used if a patient is hypersensitive to any component of the 
formulation, or who has indication of possible angle closure. In addition, drugs that 
interact with phenylephrine, such as tricyclic anti-depressants, MAO inhibitors, 
reserpine, guanethidine, and methyldopa, are contraindicated (Bartlett eta/, 1994). 
Drug characteristics of Tropicamide 
Tropicamide is an anticholinergic agent which is primarily used to dilate the 
pupil for fundus examinations and to prevent posterior synechia during uveitis or 
trauma. The cycloplegic effect of Tropicamide is also beneficial in determining 
refractive errors when a relaxed accommodative system is needed (Rengstorff and 
Doughty, 1982). Although it is classified as a cycloplegic agent, tropicamide is 
considered the drug of choice for mydriasis due to its quick onset and short 
duration of action (Bartlett and Jaanus, 1989; Bartlett eta/, 1994). As a mydriatic 
agent Tropicamide provides maximum dilation within 20-40 minutes post drop. 
The pupil usually recovers to the pre-dilation state within 6 hours of instillation 
(Bartlett et at, 1994). 
When Tropicamide is used in conjunction with punctal occlusion, systemic 
side effects are lessened. However, the patient should be educated about the 
potential for ocular and systemic effects. Ocular reactions may include increased 
intraocular pressure, transient stinging, hyperemia, blurred vision, photophobia, 
punctate keratitis, and possible allergic reactions (Bartlett eta/, 1994). Systemic 
side effects include CNS disturbances, flushing and dryness of the mouth and skin, 
headaches, a rapid irregular pulse, irritability, bladder distention, hallucinations, 
drowsiness, decreased gastrointestinal motility, coma, medullary paralysis and in 
very rare instances, death (Bartlett eta/, 1994). 
Cycloplegic mydriatics should not be used with patients who are pregnant, 
or have posterior synechia, primary open angle glaucoma, have a potential for 
angle closure glaucoma, or are hypersensitive to the formulation (Bartlett eta/, 
1994). 
The pharmacological mechanism of mydriasis 
There are two separately innervated muscles involved in pupil mydriasis, 
the iris sphincter and the iris dilator. Tropicamide blocks cholinergic stimulation to 
the sphincter muscle of the iris and the ciliary body causing both pupil dilation and 
accommodative paralysis. In contrast, phenylephrine acts as a alpha receptor 
agonist, causing contraction of the iris dilator muscle, acting on the radial fibers. 
Other non-mydriatic affects that occur simultaneously with the use of phenylephrine 
include constriction of the arteriole smooth muscle (causing "blanching" of the 
conjunctiva) and the widening of the palpebral fissure by stimulation of Muller's 
muscle. The combined use of both a parasympatholytic (tropicamide) and a 
sympathomimetic (phenylephrine) provides maximal dilation that is resistant to 
intense light stimulation (Leonard and Henrick, 1980). 
Physiological and anatomical influences on drug absorption 
One of the most important aspects of pharmacokinetics is the absorption 
phase. Without adequate absorption, drug distribution and metabolism are altered 
and the intended effect does not occur. Absorption depends on the molecular 
properties of the drug, the penetrating factor of the tissue, the patient's age, iris 
pigmentation and tear flow (Mardi et a!, 1986). 
The major topical drug absorbing tissue of the eye is the avascular cornea. 
The corneal epithelium acts as a reservoir for lipophilic drugs and the stroma stores 
hydrophilic drugs. Any disruption of the corneal epithelium can affect drug 
absorption. The use of topical anesthetic, or any abrasion to the cornea can cause 
an increase in corneal penetration of mydriatic drugs. Phenylephrine has 
characteristics that may lead to corneal epithelium disruption (Eidelhauser eta!, 
1980). This change in corneal integrity may lead to an increase in both effect and 
duration of the phenylephrine and/or tropicamide induced mydriasis (Bartlett and 
Jaanus, 1989; Bartlett eta!, 1994; Paggiarino eta!, 1993). 
Other ocular tissues and structures have limited affects on drug absorption. 
The sclera and conjunctiva account for less than one fifth of all drug absorption into 
the iris and ciliary body because they are so highly vascularized (Ahmed and 
Patton, 1985; Doane eta!, 1978). Pigment granules within the iris absorb drugs 
with lipophilic properties and slowly release that drug over a period of time. 
Previous studies have indicated that dark irides take longer to dilate than light 
colored irides but this has been insignificant in altering the dilation rate. (Dillon et 
a/, 1977; Leonard and Henrick, 1980) Furthermore, the ciliary body is involved with 
drug detoxification and elimination and is the major drug metabolizing tissue of the 
anterior segment. 
Tears play a major role in the process of drug absorption. Only 30 
microliters can be held by the palpebral conjunctiva and fornix at one time which 
includes the 8-10 microliters of normal tear volume. Therefore, too large a volume 
or instillation of too many drops will simply roll off the cheek or pass through the 
puncta resulting in no increase in the desired pharmacological effects of the drug 
(Chrai eta/, 1974; Bartlett and Jaanus, 1989). Similarly, ocular pharmaceutical 
agents may become diluted from reflex tearing if the drugs sting upon instillation 
which would further increase tear volume. However, increasing drop size has no 
affect in increasing drug absorption. 
Increased absorption of a drug may occur with people who have a 
decreased tear flow rate such as elderly patients, patients with rheumatoid arthritis, 
keratoconjunctivitis sicca, or post-menopausal women (Bartlett and Jaanus, 1989). 
Concerns about dilation 
When compared to an undilated pupil, a dilated pupil facilitates locating and 
identifying posterior segment anomalies and abnormalities by providing an 
increased viewing area. However, there are drawbacks with pupil dilation. 
Increased examination time, patient inconvenience, and the fear of systemic and 
ocular side effects are commonly cited reasons why some practitioners do not 
routinely dilate and why some patients refuse dilation (Bartlett and Jaanus, 1989). 
Most patient objections can be overcome with proper education. Most 
patients want the assurance that their optometrist is providing them with the best 
possible care. Benefits of dilation include an increased viewing area for accurate 
peripheral fundus assessment and clear stereo views to assist diagnosis. By 
simply explaining the benefits of dilation, the patient will feel more comfortable and 
assured that they are getting proper care. Also, patient comfort after the dilation 
can be enhanced by reducing the photophobic effects through use of mydriatic 
glasses or Rev-Eyes, a drug that reverses mydriasis by blocking the alpha-
adrenergic receptors in the iris dilator (Conner eta/, 1993). Patient risk associated 
with potential side effects can be minimized if the administrating doctor is 
pharmacologically current, well educated, and prudent. 
Most topically applied pharmaceuticals used for pupil dilations are 
relatively safe. Rengstorff and Doughty(1982) state that, "Cycloplegics and 
mydriatics have been extensively used throughout ophthalmic history and serious 
complications have been rare but most often contributed to dosage, use with other 
drugs, surgery, trauma, and illness." Bartlett and Jaanus (1989) also suggest that 
the avascularity of the cornea provides a direct route for drug penetration without 
absorption by systemic circulation thus minimizing systemic side effects. 
Applebaum and Jaanus (1983) presented a study demonstrating the safety of 
diagnostic pharmaceutical application (DPA) by using data collected by Southern 
California College of Optometry and 20 other private practices. Of the 12,493 DPA 
cases, only six patients elicited minor side effects with the use of tropicamide or 
phenylephrine. The best way to prevent harmful side effects is to avoid 
circumstances where known characteristics and/or conditions are expected to 
trigger unwanted reactions. The optometrist should know the properties, 
recommended uses, and precautions and contraindications of every drug he/she 
administers. 
Project goals 
The intent of this study was to investigate whether the time needed for 
maximum mydriasis could be decreased or whether the amount of mydriasis could 
be increased by altering room illumination during dilation. Based on our 
understanding of the pharmaceutical properties of tropicamide and phenylephrine, 
and the physiology involved in pupil mydriasis, we predict that pupil dilation will 
occur faster if patients are placed in a darkened room following instillation of the 
topical dilation drops rather than a well lit room. In a dark room the iris sphincter 
will relax with natural pupil dilation, and the parasympatholytic drug will not be 
opposed by light induced antagonistic muscle constriction. Likewise, the 
sympathomimetic drug will be acting as an agonist in the natural direction with 
pupil dilation during darkness. Therefore, pharmaceutical dilation in darkness 
should put the system in harmony to achieve faster and/or more complete 
mydriasis. 
SUBJECTS AND METHODS 
Subjects 
Twenty subjects, 1 0 females and 1 0 males between the ages of 19 and 37 years, 
participated in this study. All subjects reported themselves to be in good health 
and free of significant systemic, neurologic or ocular diseases. Only subjects who 
had not experienced allergies or adverse reactions to anesthetics or dilating 
agents in the past were included in this study. All participants had vision 
correctable to 20/20, unremarkable slit _lamp findings, and anterior chamber angles 
greater than three via Von Herrick technique. Prior to participation, informed 
consent was obtained from each subject. 
Methods 
The initial examination of the subjects included a complete biomicroscopy 
evaluation to assess general ocular health of each ·eye and Goldmann tonometry to 
measure intraocular pressures. One drop of tetracaine 1% was instilled into each 
lower fornix just prior to performing tonometry. Care was taken to minimize any 
systemic absorption by occluding the puncta and having the subject close his/her 
eyes for 15 seconds. Anterior chamber angles were determined by using Von 
Herrick and shadow methods. In addition, eye color was classified as either being 
light or dark. 
Subjects were then randomly placed in either a dark or a well illuminated 
room. By using a photometer in the illuminated rooms, light levels were controlled 
at 22 foot candles. A baseline horizontal pupil diameter was measured using 
Cogan's pupilometer. 
Cogan's pupilometer is a handheld card which has a series of paired 
pinholes. The separation between the paired pinholes increases by 0.5mm with 
each pair down the card. The vertical spacing is uniform between the paired 
pinholes. When the card is held at a common vertex distance from the eye, the 
subject can see through a pair of two tiny holes simultaneously. While viewing a 
distant light target, the subject subjectively moves the card up and down until the 
two holes appear to just touch without overlap or separation. From this "ideal" 
pinhole separation distance a pupil diameter can be determined (Cogan, 1941 ). 
When the procedure was performed in a light room, subjects viewed a white wall at 
six meters under ambient room illumination as previously described, whereas, 
when the procedure was performed in a dark room, subjects viewed a black light 
positioned six meters in front of them. 
After each subject was trained to properly use the Cogan's pupilometer, a 
baseline pupil diameter measurement was obtained, for each eye, in normal room 
illumination. One drop of 2.5% phenylephrine HCI was then instilled into the lower 
fornix of each eye and the timer was started. After 15 seconds, one drop of 1% 
tropicamide was instilled into each eye. In each instance, precautions were taken 
to minimize systemic absorption through the use of puncta! occlusion. Subjects 
were encouraged to keep their eyes open and to look into the distance for the 
duration of the experiment. Six minutes after instillation of the first drop, subjects 
were asked to measure their horizontal pupil diameter with the Cogan's 
pupilometer. After the subjects identified the pinhole pair that yielded touch without 
overlap or separation, the examiner then noted the pupil size equivalent from the 
front of the card. Subjects were unaware of which pupil sizes corresponded to the 
pinhole pairs. Following this pupil size determination, measurements were taken 
every two minutes until 30 minutes had elapsed. At 30 minutes, normal room 
illumination (22 foot candles) was resumed for those subjects who were dilated 
under dark illumination conditions. After a further three minutes in the light (i.e .. 33 
minutes after the installation of the drops) a final horizontal and vertical pupil 
diameter was measured using the slit lamp reticule. Tonometry was then repeated 
to check for any significant lOP changes. The subjects then returned in one week 
to complete the protocol with the alternate illumination condition. A minimum of 
one week was required between dilations to prevent any possibility of an additive 
effect of the dilation pharmaceuticals. 
In the remainder of this paper subjects dilated in a well lit room may be 
referred to as "light dilation" while those subjects dilated in a dark room may be 
referred to as "dark dilation". 
STATISTICAL ANALYSIS 
The time to maximum mydriasis was arbitrarily classified as the time after 
which subjects chose the same pinhole pair for five consecutive readings, thus 
indicating a pupil size fluctuation of no more than 0.5mm. Readings were recorded 
for both eyes and then a mean time was determined for each subject. 
Paired t-tests were used to compare the time required in the dark to the time 
required in the light for maximum mydriasis to occur. Unpaired t-tests were used to 
analyze the effects of iris color. The mean times to maximum dilation with dark 
irides were compared to those with light irides in the illuminated room. Then the 
same computations were made with the results obtained in the darkened room. 
Unpaired t-tests were used in a similar fashion to compare times to maximum 
dilation of males to females under the same illumination conditions. 
An average horizontal pupil measurement was calculated from both the 
eyes using the slit lamp reticule. Similarly, an average vertical pupil measurement 
was calculated. Paired t-tests were used to compare mean horizontal and mean 
vertical pupil diameters in a light room. The same comparison was made for data 
obtained from the dark room condition. The relative pupil area was determined by 
considering the pupil as an ellipse rather than a circle. Thus a relative pupil area 
was calculated using the formula, (1tvh)/4, where "v" is the maximum vertical pupil 
diameter and "h" is the maximum horizontal pupil diameter. A paired t-test was 
then used to compare dark·dilation versus light dilation relative pupil area for each 
subject at 33 minutes post drug installation. In addition, a paired t-test was used to 
compare mean horizontal and mean vertical pupil measurements that were taken 
under the same lighting conditions. 
The gender versus pupil size comparison was made using an unpaired t-test 
to compare the mean relative pupil area for males verses females who were dilated 
under the same lighting conditions. Similarly, an unpaired t-test was used to 
determine if iris color had any effect on the size of the dilated pupil area. 
RESULTS 
Table 1: Time to maximum mydriasis (Values in parentheses are 
standard deviations) 
Illumination level Number of Males/Females Mean time to 
subjects mydriasis in 
minutes 
light 20 1/1 19.7 (4.3) 
dark 20 1/1 18.1 {4.4} 
Time to maximum mydriasis 
Table 1 presents the mean time to maximum mydriasis, as measured by the 
Cogan's pupilometer, for the 20 subjects who experienced light dilation and dark 
dilation. Although the subjects dilated faster in a dark room with a mean time of 
18.1 minutes, compared to the mean of 19.7 minutes for dilation in a well lit room, 
the one-tailed paired t-test indicated that there was no significant difference 
(p>0.05) in the time to dilation between the light and dark dilations. 
Unpaired t-tests comparing males verses females indicated no significant 
gender difference (p>0.05). 
Unpaired t-tests showed no significant difference (p> 0.05) between light 
and dark color irides. That is, in a light room, there was no difference in the time 
required for subjects with dark irides to dilate compared to those subjects with light 
irides. Similarly, when the dilation process was completed in a dark room, there 
was no significant difference in the time to maximum dilation. 
Table 2: Mean pupil measurements at 33 minutes after tropicamide 
1% and phenylephrine HCI 2.5% were instilled (Values in parentheses 
are standard deviations) 
illumination mean horizontal mean vertical mean relative 
conditions pupil diameter in pupil diameter in pupil area in mm2 
mm mm 
light 8.12 (0.65) 8.07 (0.64) 51.73 (7.60) 
dark 7.94 (0.55) 7.91 (0.62) 49.55 (7.01) 
Relative area of pupil dilation 
Table 2 presents the slit lamp pupil measurements obtained from the 20 subjects at 
33 minutes post instillation of the mydriatic drops. When comparing the relative 
pupil area of subjects dilated in dark conditions verses light conditions using a 
paired t-test, there was a significant difference (p<0.05). Subjects dilated in a well 
lit room had a significantly increased relative pupil area compared to dark dilation. 
When looking only at the mean horizontal diameter of the pupil, dilation during light 
conditions yielded a significantly (p<0.05) larger horizontal diameter then dark 
dilation. However, the vertical pupil diameter differences fell just short of 
significance (p>0.05). This surprising finding indicates that most of the increased 
relative area obtained from light dilation is derived from the horizontal measure. 
Within the same lighting conditions, there was not a significant difference between 
the horizontal and vertical pupil diameter measurements (p>0.05). 
There was no significant pupil size relationship between males and females 
or between light and dark iride colors within the same set of illumination conditions 
using unpaired t-tests (p>0.05). 
Subjective response 
During the dark dilation procedure, when the lights were turned on 30 
minutes after drop installation, many subjects complained of discomfort due to the 
bright lights. The same subjects in the light dilation procedure did not report this 
discomfort. 
DISCUSSION: 
The goals of this project were to determine whether the speed or size of 
maximum dilation would be different if the patient was dilated in a darkened room 
versus a well lit room. In other words, do illumination conditions 30 minutes after 
drop installation, affect pupil dilation? Also, we were interested whether gender 
differences or iris color would influence dilation results. 
Contrary to our original prediction, this study showed that placing a patient in 
a dark room does not result in a significantly faster dilation than dilating the patient 
in a well lit room. Allowing the patient to dilate in a dark room did improve overall 
comfort. However, this initial comfort is short lived because the patient will soon be 
subjected to the bright lights of an indirect ophthalmoscope. Perhaps waiting for 
this procedure in a well lit room will lessen the discomfort of the bright lights to 
come. 
Based on slit lamp measurements, 33 minutes after dilation, there is a 
significant difference (p<0.05) in the pupil area when patients dilate in a dark room 
compared to in a light room. Unexpectedly, the relative pupil area obtained from 
light dilation produced a greater mean pupil area (2.18 mm2) than that from dark 
dilation. Although we do not know exact reasons why, one possible explanation 
may be that in the light, the iris is constricted and thus more area of iris and ciliary 
body is exposed and available for absorption of mydriatic agents. Surprisingly, it 
was the horizontal pupil diameter that was statistically larger, whereas the vertical 
pupil measurement was not. This may be explained by the natural pooling of the 
mydriatic in the palpebral fissure in the horizontal meridian. With the eyes open, 
fluid will tend to accumulate in the horizontal meridian along the lower lid margin 
and the blinking action may push fluid towards the fissure. In a well lit room we 
believe the lids may tend to assume a more squint type posture than in the dark, 
thus narrowing the palpebral fissure, decreasing the vertical width of the drug 
reservoir in contact with the front surface of the eye. Increased drug concentration 
along the fissure could conceivably increase the drug availability to the cornea and 
might explain the greater horizontal mydriasis obtained from a light dilation. 
Gender or iris color was not a factor in either the rate to maximum mydriasis, 
or in differences of relative pupil area. Our finding that gender has no impact on 
dilation results was expected since there are no anatomical differences between 
healthy male and female eyes that would increase or decrease drug absorption. 
Our finding that iris color has no significant effect is consistent with past research 
which has shown iris color (categorized as light or dark) has no significant effect in 
the amount or rate of dilation (Dillon et at, 1977; Leonard and Henrick, 1980). 
The ambient illumination during patient dilation is usually determined by the 
doctor rather than the patient. For patient comfort one may recommend low 
illumination during dilation. However, our results demonstrate that dilation with low 
light levels are not significantly faster and may yield a pupil area that is slightly 
smaller, although this difference is probably not clinically significant. The "bottom 
line" is that although patient comfort may be slightly enhanced with dark dilation, 
the patient is not going to be ready for the fundus examination any faster. One 
might argue that it is preferable to have the patient sit in the reception area and 
enjoy the company of friends or other patients. The additional benefits of 
undergoing dilation in a well lit room include not only the increased final dilation 
area, but also as the dilation progresses, the eyes seem to gradually adapt to the 
increased light reaching the retina. After all, it seems paradoxical during the 
dilation to place the patient in a dark room for comfort, when moments later, very 
bright lights will be aimed directly through their fully dilated pupils. In the future, 
after instillation of the mydriatic drops, we will seat our patients in a well lit room 
while the drops take effect. 
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